Business Description

Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for the treatment of metabolic diseases. Headquartered in San Diego, California, the company targets innate homeostatic pathways to address hunger-associated conditions. Its lead candidate, ARD-101, is an oral drug designed to treat hyperphagia associated with rare diseases such as Prader-Willi Syndrome.

Everything on Aardvark Therapeutics, Inc.

YoY growth —
Operating margin —
Direction —
Gross margin —
Net margin —

Leadership & board

View leadership ↗

Named Competitors

Soleno TherapeuticsRhythm PharmaceuticalsRelmada TherapeuticsBright Minds Biosciences

Customer Concentration

Aardvark is a pre-revenue, clinical-stage biopharmaceutical company with no products approved for commercial sale and has not generated any product revenue to date; accordingly, it has no commercial customers or customer concentration.

Recent SEC Filings

2026-06-12 Leadership change (directors/officers) View filing ↗
2026-05-14 Other event View filing ↗
2026-05-07 Reported quarterly results View filing ↗
2026-03-24 Entered a material agreement View filing ↗
2026-03-23 Reported quarterly results View filing ↗
2026-02-27 Other event View filing ↗
2026-02-12 Leadership change (directors/officers) (+1 more) View filing ↗
2026-02-10 Other event View filing ↗
2026-01-12 Other event View filing ↗
2025-12-10 Other event View filing ↗
2025-11-13 Reported quarterly results View filing ↗
2025-11-06 Other event View filing ↗

More Companies

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.